Alterity Therapeutics

Investor Overview

Contact Us

Governance

Events and Presentations

Analyst Coverage

Share Price

Announcements

Press Releases [2025]

Investors

Home

ATH434

Multiple System Atrophy

Pipeline

Parkinsonian Diseases

The Science

Publications & Presentations

Team

About Us

About Us Overview

Montserrat

Highly experienced leadership team with proven track record and multiple U.S. FDA approvals

ATH434 is a novel, orally administered drug candidate targeting key proteins implicated in neurodegeneration in various Parkinsonian disorders

Two completed Phase 2 clinical trials with ATH434 for patients suffering from Multiple System Atrophy (MSA), demonstrating positive treatment effect on a key clinical endpoint

U.S. Fast Track Designation and Orphan Drug Designation granted in the U.S. and EU for ATH434 for the treatment of MSA

Drug discovery team generating patentable compounds as next generation therapies

Alterity Therapeutics is a late-clinical stage biotechnology company dedicated to developing treatments for people living with neurodegenerative diseases. The Company is initially focused on developing disease modifying therapies in Parkinson’s disease and related disorders. 

Alterity has demonstrated clinically meaningful efficacy for its lead asset, ATH434, in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder. The company is actively planning a pivotal, Phase 3 trial.

In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. 

Alterity stock is traded on the ASX:ATH and Nasdaq:ATHE.